Roche’s current business arrangements with Genentech give Roche all non-US marketing and development rights to Genentech’s product line through 2015. While that may seem a long way off to some people, Genentech apparently has as many as 100 products in it’s current development pipeline, and as these products move into clinical trials, the ability to [...]
Filed under: Uncategorized | Comments Off
IMS Health data for the first quarter of 2008 in the US apparently suggest that:
the number of scripts dispensed is growing at its slowest rate in at least a decade
the rate of prescription growth has fallen steadily since early 2007
the number of scripts dispensed may actually have fallen in 2Q08
Filed under: Business strategy, Health and drug costs, health economics | Comments Off
Now this looks like a bright idea! Let’s actually talk to the ultimate payers and give them some idea what we’re thinking of moving through the development pipeline so that the payers can tell us up front what they might be prepared to pay for.
Filed under: Business strategy, Drug approvals and regulation, Drug development / clinical trials, Health and drug costs, health economics | Comments Off
